online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 1 of 10
ECPB 2017, 77(1): 5–12
Research articles

Highly Sensitive C reactive Protein (hs-CRP) as marker in Oral & Oropharyngeal malignancy


High-sensitivity C-reactive protein (hsCRP) an acute phase inflammatory reactant protein, it has been used to predict the risk of cardiovascular disease in healthy individuals and to monitor treatment responses. Epidemiological evidence also points to link between inflammation and development of cancer, i.e. long-term inflammation and dysplasia. Worldwide ~ 15 % of the cancer incidence is associated with microbial infection. NSAIDs have been used for cancer prevention in familial adenomatous polyposis. The objective of study is to evaluate the association between hs-CRP and head and neck cancer (SCCHN).

Methods: Prospective, cross sectional case-control study was under taken involving 36 SCCHN (cases) and 36 normal volunteers age matched (controls). Cases staged as per UICC TNM. The study subjects 4ml clotted blood, centrifuged, serum stored at -20 °C. hsCRP (mg/L) determined using Quantitative Immunoturbidimetric method. Statistical analysis was performed using SPSS. Results: Evaluable subjects = 72, Cases (Cancer patients) = 36 & Control = 36. Age group range 18 to 80 yrs. Mean Age Cases 59.5+9.9 v/s Control 59+9.6 yrs. M: F Cases - 25:9 v/s Control 27:9. In Cases Oral Ca – 22 (61.1 %) & Oropharynx - 14 (38.9 %). T4 – 20 (55.6 %), T3 - 8 (22.2 %) & T2 - 8 (22.2 %). N3 - 3 (8.3 %), N2 - 14 (38.9 %), N1 - 5 (13.9 %) & N0 - 14 (38.9 %). The hsCRP of Control group v/s Cancer Case group = 3.03 ± 2.61 v/s19.23 ± 19.003 respectively (P < 0.0001). hsCRP for Oral Cancer – 15.07 + 7.66 & OPX – 25.77 + 28.31. In the case group, the mean hsCRP levels with tumour size T2 was 119.36 ± 7.0, T3 was 21.32 ± 23.27, T4 was 18.3350 ± 21.0915 and with Node size N0 - 20.3 ± 35.07, N1 - 13.8 ± 5.37, N2 - 21.6 ± 25.022, N3 - 122.1 ± 1.7.

Conclusions: Inflammatory responses play decisive roles at different stages of tumor development, initiation, promotion, malignant conversion, invasion, and metastasis. This study shows serum hsCRP levels were significantly elevated in SCCHN cases compared to age matched normal control subjects. hsCRP Can be used as a surrogate marker of SCCHN. Measuring and charting hsCRP values can prove useful in determining disease progress or the effectiveness of treatments, Furthers studies are contemplated.

Received 20/11/2016

Keywords: hsCRP, CRP, Inflammation, Cancer, Head & Neck cancer, Oral cancer

Full text: PDF (Eng) 1.17M

  1. 1. Aleksandrova K, Jenab M, Boeing H, Jansen E, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition.
  2. 2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
  3. 3. Baron J, Cole B, Sandler R, Haile R, Ahnen D, Robert Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348 (10):891-9.
  4. 4. Erlinger T, Platz E, Rifai N, Helzlsouer K. C-reactive protein and the risk of incident colorectal cancer. Jama 2004;291(5):585-90.
  5. 5. Farrow B, Evers B. Inflammation and the development of pancreatic cancer. Surgical Oncology 2002;10:153-169.
  6. 6. Feller L, Wood N, Khammissa R, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med. 2010,15(6):15.
  7. 7. Flohr J, Lee J. Identical but different: mechanism of cancer development and response to treatment for human papillomavirus-related and non-related squamous cell cancer of the head and neck. S D Med 2008;61(12):453-455.
  8. 8. Ito Y, Suzuki K, Tamakoshi K, Wakai K et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study.
  9. 9. McSorley M, Alberg A, Allen D, Allen N et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Cancer Causes Control. 2008;19(6):559-67.
  10. 10. Otake T, Uezono K, Takahashi R, Fukumoto J et al. C-reactive protein and colorectal adenomas: Self Defense Forces Health Study. J Natl Cancer Inst. 2010;Feb 3;102(3):202-6.
  11. 11. Pepys M, Hirschfield G. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12.
  12. 12. Pintos J, Black M, Sadeghi N, Ghadirian P, Zeitouni A, Viscidi R et al. Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol. 2008;44(3):242-50. Epub 2007 Apr 27.
  13. 13. Thompson D, Pepys M, Wood S. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7(2):169-77.
  14. 14. Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev. 2010;11(4):1045-9.
  15. 15. Zhang S, Buring J, Lee I, Cook N, Ridker P. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med. 2005;Mar 15;142(6):I79.

Програмування -